GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cardiol Therapeutics Inc (TSX:CRDL) » Definitions » ROIC %

Cardiol Therapeutics (TSX:CRDL) ROIC % : -2,862.39% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Cardiol Therapeutics ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Cardiol Therapeutics's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2023 was -2,862.39%.

As of today (2024-05-11), Cardiol Therapeutics's WACC % is 6.80%. Cardiol Therapeutics's ROIC % is -2460.43% (calculated using TTM income statement data). Cardiol Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Cardiol Therapeutics ROIC % Historical Data

The historical data trend for Cardiol Therapeutics's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiol Therapeutics ROIC % Chart

Cardiol Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
Get a 7-Day Free Trial -205.96 -464.84 -916.56 -972.15 -3,195.92

Cardiol Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,990.15 -3,059.33 -1,839.10 -1,905.07 -2,862.39

Competitive Comparison of Cardiol Therapeutics's ROIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Cardiol Therapeutics's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardiol Therapeutics's ROIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cardiol Therapeutics's ROIC % distribution charts can be found below:

* The bar in red indicates where Cardiol Therapeutics's ROIC % falls into.



Cardiol Therapeutics ROIC % Calculation

Cardiol Therapeutics's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-29.786 * ( 1 - 0% )/( (1.062 + 0.802)/ 2 )
=-29.786/0.932
=-3,195.92 %

where

Cardiol Therapeutics's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2023 is calculated as:

ROIC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-32.116 * ( 1 - 0% )/( (1.442 + 0.802)/ 2 )
=-32.116/1.122
=-2,862.39 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cardiol Therapeutics  (TSX:CRDL) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Cardiol Therapeutics's WACC % is 6.80%. Cardiol Therapeutics's ROIC % is -2460.43% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Cardiol Therapeutics ROIC % Related Terms

Thank you for viewing the detailed overview of Cardiol Therapeutics's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardiol Therapeutics (TSX:CRDL) Business Description

Traded in Other Exchanges
Address
2265 Upper Middle Road East, Suite 602, Oakville, ON, CAN, L6H 0G5
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Cardiol Therapeutics (TSX:CRDL) Headlines

From GuruFocus

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

By GuruFocusNews GuruFocusNews 06-13-2022

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

By GuruFocusNews GuruFocusNews 06-03-2022

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

By GuruFocusNews GuruFocusNews 05-24-2022

Heart Failure and CBD -- CFN Media

By Marketwired Marketwired 02-20-2019

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

By GuruFocusNews GuruFocusNews 07-03-2022

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

By GuruFocusNews GuruFocusNews 06-23-2022